Clinical trials: Capecitabine
Breast Cancer, Breast Neoplasms
A Phase III Trial For Patients With Metastatic Breast Cancer
This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent.
- Conditions
- Breast Cancer, Breast Neoplasms, Cancer of the Breast
- Trial name
- NCT00191152
- Testing
- gemcitabine, docetaxel, capecitabine
- Where
- 65 sites in United States, Argentina and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
A Study of Ruxolitinib in Pancreatic Cancer Patients
This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
- Trial name
- NCT02119663
- Testing
- Ruxolitinib, Capecitabine
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 86 people
- Sponsor
- Incyte Corporation
Gastric Cancer, GastroEsophageal Cancer
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or…
- Trial name
- NCT03472365
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer, Gastric Cancer
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin…
- Trial name
- NCT00113581
- Testing
- EMD 72000 (matuzumab) + ECX
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Liver Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
- Trial name
- NCT02013830
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 7 sites in Australia, Hong Kong and 2 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer.
- Trial name
- NCT01442155
- Testing
- Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Gastric Cancer
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy.
- Trial name
- MATRIX EG (NCT00215644)
- Testing
- Matuzumab, Epirubicin, Cisplatin
- Where
- 22 sites in Germany, Spain and 2 more
- Volunteers
- 72 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Neoplasms
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.
- Trial name
- NCT00435409
- Testing
- Sunitinib + Capecitabine, Capecitabine
- Where
- 169 sites in United States, Austria and 16 more
- Volunteers
- 442 people
- Sponsor
- Pfizer
Metastatic Breast Cancer or Metastatic Colorectal Cancer
A Bioequivalence Study of Capecitabine Tablets
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2.
- Trial name
- NCT01846650
- Testing
- Capecitabine tablets, XELODA
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
This study will evaluate the efficacy and safety of treatment with oral capecitabine or intravenous (IV) 5-fluorouracil (5-FU), in combination with epirubicin and cyclophosphamide, prior to surgery in participants with breast…
- Trial name
- NCT02846428
- Testing
- 5-Fluorouracil, Capecitabine, Cyclophosphamide
- Where
- 21 sites in France
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline…
- Trial name
- NCT00373113
- Testing
- Capecitabine, Sunitinib malate
- Where
- 123 sites in Argentina, Australia and 21 more
- Volunteers
- 482 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal…
- Trial name
- NCT00069108
- Testing
- 5 FU, Leucovorin, Oxaliplatin
- Where
- 87 sites in United States, Belgium and 18 more
- Volunteers
- 627 people
- Sponsor
- Hoffmann-La Roche